FDA Sending Fewer Warning Letters Regarding Clinical Trials

Clinical Trials Advisor
KEYWORDS FDA / Warning
A A

Despite a recent flurry of FDA warning letters regarding clinical trials, a CTA analysis shows a steady decline in the number of warning letters sent to sponsors, clinical investigators and institutional review boards (IRBs) over the past year.

To View This Article:

Login

Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $10.00